Abstract |
We have previously reported that NM23 genes are overexpressed in various hematological malignancies and that serum NM23-H1 protein levels are useful for predicting patient outcomes. In this study we assessed the clinical implications of serum NM23-H1 protein on neuroblastoma. We examined serum NM23-H1 protein levels in 217 patients with neuroblastoma, including 131 found by mass-screening and 86 found clinically by an enzyme-linked immunosorbent assay, and determined the association between levels of this protein, and known prognostic factors or the clinical outcome. The serum NM23-H1 protein level was higher in neuroblastoma patients than in control children (P < 0.0001). Patients with MYCN amplification had higher serum NM23-H1 levels than those with a single copy of MYCN. Overall survival was assessed in the 86 patients found clinically, and was found to be worse in patients with higher serum MN23-H1 levels (> or = 250 ng/mL) than in those with lower levels (< 250 ng/mL; P = 0.034). The higher level of NM23-H1 was correlated with a worse outcome in patients with a single MYCN copy, or in those younger than 12 months of age. Serum NM23-H1 protein levels may contribute to predictions of clinical outcome in patients with neuroblastoma.
|
Authors | Junko Okabe-Kado, Takashi Kasukabe, Yoshio Honma, Ryoji Hanada, Akira Nakagawara, Yasuhiko Kaneko |
Journal | Cancer science
(Cancer Sci)
Vol. 96
Issue 10
Pg. 653-60
(Oct 2005)
ISSN: 1347-9032 [Print] England |
PMID | 16232196
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- MYCN protein, human
- N-Myc Proto-Oncogene Protein
- NM23 Nucleoside Diphosphate Kinases
- Nuclear Proteins
- Oncogene Proteins
- NME1 protein, human
- Nucleoside-Diphosphate Kinase
|
Topics |
- Age Factors
- Biomarkers, Tumor
(blood)
- Case-Control Studies
- Child
- Child, Preschool
- Enzyme-Linked Immunosorbent Assay
- Female
- Gene Dosage
- Humans
- Infant
- Infant, Newborn
- Male
- N-Myc Proto-Oncogene Protein
- NM23 Nucleoside Diphosphate Kinases
- Neuroblastoma
(genetics, pathology, therapy)
- Nuclear Proteins
(analysis)
- Nucleoside-Diphosphate Kinase
(blood)
- Oncogene Proteins
(analysis)
- Prognosis
|